DOP2021000100A - COMPUESTOS TETRÁMEROS ClCLICOS COMO INHIBIDORES DE PROPROTElNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) PARA EL TRATAMIENTO DE TRASTORNOS METABÓLICOS. - Google Patents
COMPUESTOS TETRÁMEROS ClCLICOS COMO INHIBIDORES DE PROPROTElNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) PARA EL TRATAMIENTO DE TRASTORNOS METABÓLICOS.Info
- Publication number
- DOP2021000100A DOP2021000100A DO2021000100A DO2021000100A DOP2021000100A DO P2021000100 A DOP2021000100 A DO P2021000100A DO 2021000100 A DO2021000100 A DO 2021000100A DO 2021000100 A DO2021000100 A DO 2021000100A DO P2021000100 A DOP2021000100 A DO P2021000100A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pcsk9
- treatment
- tetramerous
- inhibitors
- cyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a inhibidores de PCSK9 de utilidad en el tratamiento del metabolismo de los lípidos del colesterol y otras enfermedades en las que PCSK9 interviene, que tienen la fórmula (I): (I), o una sal, hidrato, solvato, profármaco, estereoisómero, N-óxido o tautómero farmacéuticamente aceptable de los mismos, en donde R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, y X3 están descriptos en la presente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772030P | 2018-11-27 | 2018-11-27 | |
US201962924828P | 2019-10-23 | 2019-10-23 | |
PCT/IB2019/060201 WO2020110009A1 (en) | 2018-11-27 | 2019-11-26 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2021000100A true DOP2021000100A (es) | 2021-06-30 |
Family
ID=68808460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000100A DOP2021000100A (es) | 2018-11-27 | 2021-05-24 | COMPUESTOS TETRÁMEROS ClCLICOS COMO INHIBIDORES DE PROPROTElNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) PARA EL TRATAMIENTO DE TRASTORNOS METABÓLICOS. |
Country Status (24)
Country | Link |
---|---|
US (2) | US11026993B2 (es) |
EP (1) | EP3887365A1 (es) |
JP (1) | JP2022507957A (es) |
KR (1) | KR20210096154A (es) |
CN (1) | CN113166114A (es) |
AU (1) | AU2019387294B2 (es) |
BR (1) | BR112021009857A2 (es) |
CA (1) | CA3115960A1 (es) |
CL (1) | CL2021001365A1 (es) |
CO (1) | CO2021006895A2 (es) |
CR (1) | CR20210267A (es) |
CU (1) | CU20210043A7 (es) |
DO (1) | DOP2021000100A (es) |
EC (1) | ECSP21036194A (es) |
IL (1) | IL283374A (es) |
JO (1) | JOP20210120A1 (es) |
MA (1) | MA54284A (es) |
MX (1) | MX2021006069A (es) |
PE (1) | PE20211658A1 (es) |
PH (1) | PH12021551049A1 (es) |
SG (1) | SG11202103807WA (es) |
TW (1) | TW202038990A (es) |
UY (1) | UY38485A (es) |
WO (1) | WO2020110009A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11882610B2 (en) * | 2020-08-13 | 2024-01-23 | Qualcomm Incorporated | Establishing connections using multiple subscriber identity modules via a single communication link |
CN114163343A (zh) * | 2021-12-10 | 2022-03-11 | 许昌学院 | 含氟氨基酸及衍生物含氟多肽的制备方法以及应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
EP0512042B1 (en) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
IT1291776B1 (it) | 1997-02-07 | 1999-01-21 | Menarini Ricerche Spa | Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista |
IT1304888B1 (it) | 1998-08-05 | 2001-04-05 | Menarini Ricerche Spa | Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
IT1307809B1 (it) | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
JP2003530343A (ja) | 2000-04-12 | 2003-10-14 | ノバルティス アクチエンゲゼルシャフト | アルドステロンシンターゼインヒビター単体またはat1−レセプターアンタゴニストとの組み合わせの新規医薬使用 |
EP1297826A1 (en) | 2001-09-27 | 2003-04-02 | Menarini Ricerche S.p.A. | Nasal pharmaceutical compositions containing a NK-2 antagonist |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
WO2003104200A1 (en) | 2002-06-07 | 2003-12-18 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
CN1795193B (zh) | 2003-05-20 | 2010-08-18 | 诺瓦提斯公司 | 用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物 |
JP2008500998A (ja) | 2004-05-28 | 2008-01-17 | シュペーデル・エクスペリメンタ・アーゲー | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
EP1749005A1 (en) | 2004-05-28 | 2007-02-07 | Speedel Experimenta AG | Tetrahydro-imidazo ¬1,5-a| pyridin derivatives as aldosterone synthase inhibitors |
CA2568164A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
TW200611897A (en) | 2004-07-09 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
PL2004607T3 (pl) | 2006-03-31 | 2012-03-30 | Novartis Ag | Pochodne kwasu (4-(4-[6-(trifluorometylopirydyn-3-yloamino)-N-zawierające-heteroarylo]-fenylo)-cykloheksylo)-octowego i ich farmaceutyczne zastosowania |
US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
EP2057163A1 (en) | 2006-08-25 | 2009-05-13 | Novartis AG | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
US8436035B2 (en) | 2006-12-18 | 2013-05-07 | Novartis Ag | Organic compounds |
US8143278B2 (en) | 2006-12-18 | 2012-03-27 | Novartis Ag | Organic compounds |
CN101578272A (zh) | 2006-12-18 | 2009-11-11 | 诺瓦提斯公司 | 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途 |
AU2008234957A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Heterocyclic spiro-compounds |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
JP2010538071A (ja) | 2007-09-07 | 2010-12-09 | セラヴァンス, インコーポレーテッド | 二重作用性降圧剤 |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
EP2297113A1 (en) | 2008-04-29 | 2011-03-23 | Theravance, Inc. | Dual-acting antihypertensive agents |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
PL2358737T3 (pl) | 2008-10-23 | 2017-10-31 | Steba Biotech S A | Peptydomimetyki zawierające RGD i ich zastosowania |
CN102803217B (zh) | 2009-05-15 | 2015-06-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基吡啶 |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
ES2582395T3 (es) | 2009-05-28 | 2016-09-12 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
CN102596941A (zh) | 2009-10-01 | 2012-07-18 | 卡迪拉保健有限公司 | 用于治疗血脂异常和相关疾病的化合物 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
CN102725305B (zh) | 2009-11-23 | 2016-08-24 | 帕拉丁科技公司 | 黑皮质素-1受体特异性环肽 |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
PT2651896E (pt) | 2010-12-15 | 2015-11-03 | Theravance Biopharma R&D Ip Llc | Inibidores de neprilisina |
CN103380119B (zh) | 2011-02-17 | 2016-02-17 | 施万生物制药研发Ip有限责任公司 | 作为脑啡肽酶抑制剂的经取代的氨基丁酸衍生物 |
EP2714662B1 (en) | 2011-05-31 | 2017-10-11 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
JP5885832B2 (ja) | 2011-05-31 | 2016-03-16 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ネプリライシン阻害剤 |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
MX356260B (es) | 2012-06-08 | 2018-05-21 | Theravance Biopharma R&D Ip Llc | Inhibidores de la neprilisina. |
DE102012014480A1 (de) | 2012-07-21 | 2014-01-23 | Daimler Ag | Aufbau eines Innendekors |
ME02626B (me) | 2012-08-08 | 2017-06-20 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilisina |
WO2014029022A1 (en) | 2012-08-21 | 2014-02-27 | Abdelmalik Slassi | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
EP2956464B1 (en) | 2013-02-14 | 2018-03-28 | Novartis AG | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
PL2964616T3 (pl) | 2013-03-05 | 2017-10-31 | Theravance Biopharma R&D Ip Llc | Inhibitory neprylizyny |
WO2014150395A1 (en) | 2013-03-15 | 2014-09-25 | Shifa Biomedical Corporation | Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
MX2016009760A (es) | 2014-01-30 | 2016-11-08 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina. |
CA2934898A1 (en) | 2014-01-30 | 2015-08-06 | Theravance Biopharma R&D Ip, Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
-
2019
- 2019-11-22 UY UY0001038485A patent/UY38485A/es unknown
- 2019-11-25 TW TW108142721A patent/TW202038990A/zh unknown
- 2019-11-26 JP JP2021529266A patent/JP2022507957A/ja active Pending
- 2019-11-26 MA MA054284A patent/MA54284A/fr unknown
- 2019-11-26 PE PE2021000749A patent/PE20211658A1/es unknown
- 2019-11-26 CR CR20210267A patent/CR20210267A/es unknown
- 2019-11-26 CU CU2021000043A patent/CU20210043A7/es unknown
- 2019-11-26 AU AU2019387294A patent/AU2019387294B2/en not_active Ceased
- 2019-11-26 EP EP19816905.4A patent/EP3887365A1/en active Pending
- 2019-11-26 BR BR112021009857-7A patent/BR112021009857A2/pt not_active Application Discontinuation
- 2019-11-26 WO PCT/IB2019/060201 patent/WO2020110009A1/en unknown
- 2019-11-26 US US16/695,843 patent/US11026993B2/en active Active
- 2019-11-26 CA CA3115960A patent/CA3115960A1/en active Pending
- 2019-11-26 KR KR1020217019281A patent/KR20210096154A/ko unknown
- 2019-11-26 SG SG11202103807WA patent/SG11202103807WA/en unknown
- 2019-11-26 MX MX2021006069A patent/MX2021006069A/es unknown
- 2019-11-26 JO JOP/2021/0120A patent/JOP20210120A1/ar unknown
- 2019-11-26 CN CN201980076002.XA patent/CN113166114A/zh active Pending
-
2021
- 2021-03-12 US US17/200,471 patent/US11813306B2/en active Active
- 2021-05-06 PH PH12021551049A patent/PH12021551049A1/en unknown
- 2021-05-21 EC ECSENADI202136194A patent/ECSP21036194A/es unknown
- 2021-05-23 IL IL283374A patent/IL283374A/en unknown
- 2021-05-24 DO DO2021000100A patent/DOP2021000100A/es unknown
- 2021-05-25 CO CONC2021/0006895A patent/CO2021006895A2/es unknown
- 2021-05-25 CL CL2021001365A patent/CL2021001365A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021009857A2 (pt) | 2021-08-17 |
TW202038990A (zh) | 2020-11-01 |
MX2021006069A (es) | 2021-07-06 |
EP3887365A1 (en) | 2021-10-06 |
WO2020110009A1 (en) | 2020-06-04 |
PH12021551049A1 (en) | 2021-12-06 |
CA3115960A1 (en) | 2020-06-04 |
CU20210043A7 (es) | 2022-01-13 |
AU2019387294A1 (en) | 2021-05-13 |
IL283374A (en) | 2021-07-29 |
ECSP21036194A (es) | 2021-06-30 |
SG11202103807WA (en) | 2021-06-29 |
CN113166114A (zh) | 2021-07-23 |
JP2022507957A (ja) | 2022-01-18 |
UY38485A (es) | 2020-06-30 |
CO2021006895A2 (es) | 2021-06-10 |
CR20210267A (es) | 2021-08-16 |
AU2019387294B2 (en) | 2022-09-08 |
PE20211658A1 (es) | 2021-08-24 |
KR20210096154A (ko) | 2021-08-04 |
US20210252103A1 (en) | 2021-08-19 |
JOP20210120A1 (ar) | 2023-01-30 |
US20200164024A1 (en) | 2020-05-28 |
CL2021001365A1 (es) | 2022-01-14 |
MA54284A (fr) | 2022-03-02 |
US11813306B2 (en) | 2023-11-14 |
US11026993B2 (en) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
DOP2018000150A (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
CO2019009722A2 (es) | Dendrímeros terapéuticos | |
DOP2021000100A (es) | COMPUESTOS TETRÁMEROS ClCLICOS COMO INHIBIDORES DE PROPROTElNA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9) PARA EL TRATAMIENTO DE TRASTORNOS METABÓLICOS. | |
CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
CO2017004994A2 (es) | Análogos de urea unidos sustituidos como moduladores de sirtuina | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
EA201890616A1 (ru) | Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов | |
AR106352A1 (es) | Compuestos de aminotioléster o las sales farmacéuticamente aceptables del mismo, para usar en el tratamiento del cáncer | |
DOP2013000004A (es) | Agentes terapeuticos 976 | |
UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano |